on The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group, Inc. Discloses Position in Avadel Pharmaceuticals
The Vanguard Group, Inc. has submitted a Form 8.3 regarding its interests in Avadel Pharmaceuticals plc. The disclosure, dated 11 December 2025, outlines Vanguard's position under the Irish Takeover Panel Act. This form is a regulatory requirement for entities holding significant interests in a company subject to a takeover.
The report reveals Vanguard's ownership of 5,593,994 ordinary shares, representing 5.74% of Avadel Pharmaceuticals. Additionally, Vanguard disclosed recent transactions involving Avadel's securities. It purchased 7,816 shares and sold 2,928 shares, both at USD 21.48 per share.
No cash-settled or stock-settled derivatives, nor any other complex transactions, were reported at this time. Furthermore, there are no current agreements or understandings related to voting rights, options, or derivatives tied to Avadel Pharmaceuticals.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news